Your browser doesn't support javascript.
loading
Prophylactic acid suppressants in patients with primary neurologic injury: A systematic review and meta-analysis of randomized controlled trials.
Daou, Marietou; Dionne, Joanna C; Teng, Jennifer F T; Taran, Shaurya; Zytaruk, Nicole; Cook, Deborah; Wilcox, M Elizabeth.
Afiliação
  • Daou M; Toronto Western Hospital, Toronto, Ontario, Canada.
  • Dionne JC; Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.
  • Teng JFT; Department of Pharmacy, University Health Network, Toronto, Canada; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada.
  • Taran S; Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Canada; Department of Medicine (Respirology), University Health Network, Toronto, Canada.
  • Zytaruk N; St. Joseph's HealthCare Hamilton, Hamilton, Ontario, Canada.
  • Cook D; Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada; St. Joseph's HealthCare Hamilton, Hamilton, Ontario, Canada.
  • Wilcox ME; Toronto Western Hospital, Toronto, Ontario, Canada; Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Canada; Department of Medicine (Respirology), University Health Network, Toronto, Canada. Electronic address: elizabeth.wilcox@mail.utoronto.ca.
J Crit Care ; 71: 154093, 2022 10.
Article em En | MEDLINE | ID: mdl-35714455
ABSTRACT

PURPOSE:

Neurocritical care patients are at risk of stress-induced gastrointestinal ulceration. We performed a systematic review and meta-analysis of stress ulcer prophylaxis (SUP) in critically ill adults admitted with a primary neurologic injury. MATERIALS AND

METHODS:

We included randomized controlled trials (RCTs) comparing SUP with histamine-2-receptor antagonists (H2RAs) or proton pump inhibitors (PPIs) to placebo/no prophylaxis, as well as to each other. The primary outcome was in-ICU gastrointestinal bleeding (GIB). Predefined secondary outcomes were all-cause 30-day mortality, ICU length of stay (LOS), nosocomial pneumonia, and other complications.

RESULTS:

We identified 14 relevant trials enrolling 1036 neurocritical care patients; 11 trials enrolling 930 patients were included in the meta-analysis. H2RAs resulted in a lower incidence of GIB as compared to placebo or no prophylaxis (Risk ratio [RR] 0.42, 95% CI 0.30-0.58; p < 0.001); PPIs with a lower risk of GIB compared to placebo/no prophylaxis (RR 0.37, 95% CI 0.23-0.59; p < 0.001). No significant difference was observed in GIB comparing PPIs with H2RAs (RR 0.53, 95% CI 0.26-1.06; p = 0.07; I2 = 0%).

CONCLUSIONS:

In neurocritical care patients, the overall high or unclear risk of bias of individual trials, the low event rates, and modest sample sizes preclude strong clinical inferences about the utility of SUP.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Úlcera Péptica / Úlcera Gástrica Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Úlcera Péptica / Úlcera Gástrica Idioma: En Ano de publicação: 2022 Tipo de documento: Article